Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607 · see citing works

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,380 · see citing works

APE: Analyses of Phylogenetics and Evolution in R language

Paradis, E., Claude, J., & Strimmer, K. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg412 · Cited by 12,037 · see citing works

A framework for variation discovery and genotyping using next-generation DNA sequencing data

DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,216 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · see citing works

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,838 · see citing works

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint

Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,822 · see citing works

Mutational landscape and significance across 12 major cancer types

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

Comprehensive molecular characterization of clear cell renal cell carcinoma

The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · see citing works

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H. M., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,473 · see citing works

A census of human cancer genes

Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · see citing works

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · see citing works

Somatic mutations affect key pathways in lung adenocarcinoma

Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · see citing works

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377 · see citing works

Tracking the Evolution of Non–Small-Cell Lung Cancer

Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · see citing works

Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism

Liu, C., Li, Y., Semënov, M. V., Han, C., Baeg, G., Tan, Y., Zhang, Z., Lin, X., & He, X. (2002) · Cell · doi:10.1016/s0092-8674(02)00685-2 · Cited by 2,066 · see citing works

Absolute quantification of somatic DNA alterations in human cancer

Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,003 · see citing works

Pan-cancer patterns of somatic copy number alteration

Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C., Wala, J. A., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,843 · see citing works

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · see citing works

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works

Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs

Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,589 · see citing works

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379 · see citing works

Allele-specific copy number analysis of tumors

Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,231 · see citing works

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

Gerlinger, M., Horswell, S. D., Larkin, J., Rowan, A., Salm, M., Varela, I., Fisher, R. A., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,211 · see citing works

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200 · see citing works

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K., Maher, C. A., Fulton, R. S., Fulton, L., Wallis, J. W., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,144 · see citing works

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117 · see citing works

Characterizing the cancer genome in lung adenocarcinoma

Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105 · see citing works

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · see citing works

Clock-like mutational processes in human somatic cells

Alexandrov, L. B., Jones, P. H., Wedge, D. C., Sale, J. E., Campbell, P. J., Nik‐Zainal, S., & Stratton, M. R. (2015) · Nature Genetics · doi:10.1038/ng.3441 · Cited by 1,038 · see citing works

PyClone: statistical inference of clonal population structure in cancer

Roth, A. J. L., Khattra, J. S., Yap, D., Wan, A. N. C., Laks, E., Biele, J., Ha, G., Aparicio, S. A. J. R., Bouchard‐Côté, A., & Shah, S. P. (2014) · Nature Methods · doi:10.1038/nmeth.2883 · Cited by 1,002 · see citing works

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965 · see citing works

<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation

Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710 · see citing works

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z., & Swanton, C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1408 · Cited by 685 · see citing works

Identification of neutral tumor evolution across cancer types

Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A., & Sottoriva, A. (2016) · Nature Genetics · doi:10.1038/ng.3489 · Cited by 628 · see citing works

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

Marusyk, A., Tabassum, D. P., Altrock, P. M., Almendro, V., Michor, F., & Polyák, K. (2014) · Nature · doi:10.1038/nature13556 · Cited by 588 · see citing works

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581 · see citing works

A Genomics-Based Classification of Human Lung Tumors

Thomas, R. K., Buettner, R., & Wolf, J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 508 · see citing works

Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution

Dewhurst, S. M., McGranahan, N., Burrell, R. A., Rowan, A., Gronroos, E. C., Endesfelder, D., Joshi, T., Mouradov, D., Gibbs, P., Ward, R. L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0285 · Cited by 450 · see citing works

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient

Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 449 · see citing works

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430 · see citing works

Tumour heterogeneity and the evolution of polyclonal drug resistance

Burrell, R. A., & Swanton, C. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.005 · Cited by 417 · see citing works

Impact of Metabolic Heterogeneity on Tumor Growth, Invasion, and Treatment Outcomes

Robertson‐Tessi, M., Gillies, R. J., Gatenby, R. A., & Anderson, A. R. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1428 · Cited by 274 · see citing works

Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation

Pilati, C., Letouzé, É., Nault, J., Imbeaud, S., Boulai, A., Caldéraro, J., Poussin, K., Franconi, A., Couchy, G., Morcrette, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.005 · Cited by 271 · see citing works

Mutations of the p53 Gene as a Predictor of Poor Prognosis in Patients With Non-Small-Cell Lung Cancer

Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., & Shirakusa, T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.24.2018 · Cited by 211 · see citing works

High-throughput Phenotyping of Lung Cancer Somatic Mutations

Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C. R., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M. B., Hogstrom, L. J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 207 · see citing works

Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers

Parikh, C., Janakiraman, V., Wu, W., Foo, C. K., Kljavin, N. M., Chaudhuri, S., Stawiski, E. W., Lee, B., Lin, J. M., Li, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204384109 · Cited by 146 · see citing works

Dynamics of Tumor Heterogeneity Derived from Clonal Karyotypic Evolution

Laughney, A. M., Elizalde, S., Genovese, G., & Bakhoum, S. F. W. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.065 · Cited by 122 · see citing works

EMu: probabilistic inference of mutational processes and their localization in the cancer genome

Fischer, A., Illingworth, C. J. R., Campbell, P., & Mustonen, V. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r39 · Cited by 108 · see citing works

β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

Nakayama, S., Sng, N., Carretero, J., Welner, R. S., Hayashi, Y., Yamamoto, M., Tan, A. J., Yamaguchi, N., Yasuda, H., Li, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0184 · Cited by 91 · see citing works

Lung Adenocarcinoma of Never Smokers and Smokers Harbor Differential Regions of Genetic Alteration and Exhibit Different Levels of Genomic Instability

Thu, K. L., Vucic, E. A., Chari, R., Zhang, W., Lockwood, W. W., English, J. C., Fu, R., Wang, P., Feng, Z., MacAulay, C. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033003 · Cited by 77 · see citing works

Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma

Broët, P., Dalmasso, C., Tan, E. H., Alifano, M., Zhang, S., Wu, J., Lee, M. H., Régnard, J., Lim, W., Koong, H. N., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2185 · Cited by 73 · see citing works

Why imatinib remains an exception of cancer research

Horne, S. D., Stevens, J. B., Abdallah, B. Y., Liu, G., Bremer, S. W., Ye, C. J., & Heng, H. H. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24233 · Cited by 53 · see citing works

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status

Planck, M., Edlund, K., Botling, J., Micke, P., Isaksson, S., & Staaf, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078614 · Cited by 36 · see citing works

Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Jain, A., Lim, C., Gan, E. M., Ng, D. Z., Ng, Q. S., Ang, M. K., Takano, A., Chan, K. S., Tan, W. M., Kanesvaran, R., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123587 · Cited by 32 · see citing works

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History

Karlsson, A., Ringnér, M., Lauss, M., Botling, J., Micke, P., Planck, M., & Staaf, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0246 · Cited by 30 · see citing works

The Genomic Landscape of Cancers

Heng, H. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804310-3.00005-3 · Cited by 14 · see citing works

Concurrent genetic alterations identified by next-generation sequencing in pre-treatment, metastatic EGFR-mutant lung cancers.

Yu, H. A., Jordan, E., Ni, A., Feldman, D., Rodríguez, C., Kim, H. R., Kris, M. G., Solit, D. B., Berger, M. F., Ladanyi, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9053 · Cited by 13 · see citing works

The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia

Ong, S. T., Pathiraja, T. N., Javed, A., Soh, X. X. S., Malik, S., Tan, J. H. J., Ko, T. K., Chuah, C. T. H., Takahashi, N., Bhatia, R., et al. (2015) · Blood · doi:10.1182/blood.v126.23.3737.3737 · Cited by 4 · see citing works

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370 · see citing works

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

Lim, Z.-F., & Ma, P. C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0818-2 · Cited by 639 · see citing works

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Xu, J., Zhang, C., Wang, X., Zhai, L., Ma, Y., Mao, Y., Qian, K., Sun, C., Liu, Z., Jiang, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.043 · Cited by 612 · see citing works

Genomic landscape of lung adenocarcinoma in East Asians

Chen, J., Yang, H., Teo, A. S. M., Amer, L. B., Sherbaf, F. G., Tan, C. Q., Alvarez, J. J. S., Lu, B., Lim, J. Q., Takano, A. M., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0569-6 · Cited by 511 · see citing works

Drug resistance to targeted therapeutic strategies in non-small cell lung cancer

Liu, W., Du, Y., Wen, R. M., Yang, M., & Xu, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107438 · Cited by 218 · see citing works

Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma

Zhang, C., Zhang, J. J., Xu, F.-P., Wang, Y.-G., Xie, Z., Su, J., Dong, S., Nie, Q., Shao, Y. W., Zhou, Q. H., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.031 · Cited by 199 · see citing works

Revisiting neoadjuvant therapy in non-small-cell lung cancer

Saw, S. P. L., Ong, B., Chua, K. L. M., Takano, A. M., & Tan, D. S. W. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00383-1 · Cited by 204 · see citing works

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Roper, N., Brown, A., Wei, J. S., Pack, S., Trindade, C. J., Kim, C., Restifo, O., Gao, S., Sindiri, S., Mehrabadi, F. R., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100007 · Cited by 179 · see citing works

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim, Y., Lee, B., Shim, J. H., Lee, S.-H., Park, W.-Y., Choi, Y.-L., Sun, J.-M., Ahn, J. S., Ahn, M.-J., & Park, K. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.150 · Cited by 174 · see citing works

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma

Vokes, N. I., Chambers, E. S., Nguyen, T. T., Coolidge, A., Lydon, C., Le, X., Sholl, L. M., Heymach, J. V., Nishino, M., Allen, E. M. V., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.02.011 · Cited by 167 · see citing works

MET alterations in NSCLC—Current Perspectives and Future Challenges

Remón, J., Hendriks, L. E. L., Mountzios, G., García‐Campelo, R., Saw, S. P. L., Uprety, D., Recondo, G., Villacampa, G. J., & Reck, M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.015 · Cited by 150 · see citing works

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

Su, S., Dong, Z., Xie, Z., Yan, L., Li, Y., Su, J., Liu, S. M., Yin, K., Chen, R., Huang, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.016 · Cited by 144 · see citing works

Clonal <i>MET</i> Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

Lai, G. G. Y., Lim, T. H., Lim, J., Liew, P. J. R., Kwang, X. L., Nahar, R., Aung, Z. W., Takano, A., Lee, Y. Y., Lau, D. P. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00177 · Cited by 118 · see citing works

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

Zhao, H., Yao, W., Min, X., Gu, K., Yu, G., Zhang, Z., Cui, J., Miao, L., Zhang, L., Yuan, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.006 · Cited by 120 · see citing works

Tumor mutational burden in lung cancer: a systematic literature review

Willis, C., Fiander, M., Tran, D., Korytowsky, B., Thomas, J.-M., Calderon, F., Zyczynski, T. M., Brixner, D. I., & Stenehjem, D. D. (2019) · Oncotarget · doi:10.18632/oncotarget.27287 · Cited by 95 · see citing works

Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein–Barr virus by whole-genome sequencing

Tu, C., Zeng, Z., Qi, P., Li, X., Guo, C. J., Xiong, F., Xiang, B., Zhou, M., Liao, Q., Yu, J., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy108 · Cited by 93 · see citing works

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development

Corvaja, C., Passaro, A., Attili, I., Aliaga, P. T., Spitaleri, G., Signore, E. D., & de Marinis, F. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102824 · Cited by 91 · see citing works

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Guo, Y., Song, J., Wang, Y., Huang, L., Sun, L., Zhao, J., Zhang, S., Jing, W., Ma, J., & Han, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.610923 · Cited by 85 · see citing works

Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer

Weeden, C. E., Gayevskiy, V., Marceaux, C., Batey, D., Tan, T., Yokote, K., Ribera, N. T., Clatch, A., Christo, S. N., Teh, C. E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.019 · Cited by 81 · see citing works

Genomic characterisation of pulmonary subsolid nodules: mutational landscape and radiological features

Li, Y., Li, X., Li, H., Zhao, Y., Liu, Z., Sun, K., Zhu, X., Qi, Q., An, B., Shen, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01409-2019 · Cited by 78 · see citing works

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Liu, S., Bao, H., Wang, Q., Mao, W., Chen, Y., Tong, X., Xu, S.-T., Wu, L., Wei, Y., Liu, Y.-Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26806-7 · Cited by 77 · see citing works

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

Tan, D. S. W., Leighl, N. B., Riely, G. J., Yang, J. C., Sequist, L. V. D., Wolf, J., Seto, T., Felip, E., Ponce-Aix, S., Jonnaert, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30267-x · Cited by 75 · see citing works

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition

Lin, J. J., Langenbucher, A., Gupta, P., Yoda, S., Fetter, I. J., Rooney, M. M., Do, A., Kem, M., Prutisto-Chang, K., Oh, A., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0127-9 · Cited by 72 · see citing works

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Xu, L., Xi, J., Zhong, W., Mao, W., Wu, L., Shen, Y., Liu, Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.020 · Cited by 71 · see citing works

Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Ahn, E. R., Mangat, P. K., Garrett-Mayer, E. S., Halabi, S., Dib, E. G., Haggstrom, D. E., Alguire, K. B., Calfa, C. J., Cannon, T. L., Crilley, P. A., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00037 · Cited by 69 · see citing works

Advanced technological tools to study multidrug resistance in cancer

Andrei, L., Kasas, S., Ochoa, I., Stanković, T., Korsnes, M. S., Václavíková, R., Assaraf, Y. G., & Pešić, M. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100658 · Cited by 67 · see citing works

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

Stockhammer, P., Grant, M. J., Wurtz, A., Foggetti, G., Expósito, F., Gu, J., Zhao, H., Choi, J., Chung, S. T., Li, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.001 · Cited by 67 · see citing works

Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer

Fang, Y. V., Wang, Y., Zeng, D., Zhi, S., Shu, T., Huang, N., Zheng, S., Wu, J., Liu, Y., Huang, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1951019 · Cited by 65 · see citing works

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

Nanjo, S., Wu, W., Karachaliou, N., Blakely, C. M., Suzuki, J., Chou, Y., Ali, S. M., Kerr, D. L., Olivas, V. R., Shue, J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci145099 · Cited by 69 · see citing works

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis

Lei, T., Xu, T., Zhang, N., Zou, X., Kong, Z., Wei, C., & Wang, Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106668 · Cited by 66 · see citing works

Addressing cellular heterogeneity in tumor and circulation for refined prognostication

Lim, S. B., Yeo, T., Lee, W. D., Bhagat, A. A. S., Tan, S. J., Tan, D. S. W., Lim, W., & Lim, C. T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907904116 · Cited by 62 · see citing works

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)

Li, X.-M., Li, W., Lin, J., Yan, H., Tu, H., Chen, H., Wang, B.-C., Wang, Z., Zhou, Q. H., Zhang, X., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.001 · Cited by 62 · see citing works

A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer

Middleton, G., Robbins, H. L., André, F., & Swanton, C. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.004 · Cited by 58 · see citing works

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

Pros, E., Saigí, M., Alameda, D., Gómez‐Mariano, G., Martínez–Delgado, B., Alburquerque-Béjar, J. J., Carretero, J., Tonda, R., Esteve‐Codina, A., Català, I., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.09.001 · Cited by 55 · see citing works

Emerging nanotechnologies for targeting antimicrobial resistance

Weldrick, P. J., Wang, A., Halbus, A. F., & Paunov, V. N. (2022) · Nanoscale · doi:10.1039/d1nr08157h · Cited by 55 · see citing works

Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET

Pal, A. S., Agredo, A., Lanman, N. A., Son, J., Sohal, I. S., Bains, M., Li, C., Clingerman, J., Gates, K., & Kasinski, A. L. (2022) · Cancer Research · doi:10.1158/0008-5472.can-20-0821 · Cited by 57 · see citing works

Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer

Zhou, H., Hu, Y., Luo, R., Zhao, Y., Pan, H., Ji, L., Zhou, T., Zhang, L., Long, H., Fu, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25787-x · Cited by 54 · see citing works

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Kawachi, H., Tamiya, M., Tamiya, A., Ishii, S., Hirano, K., Matsumoto, H., Fukuda, Y., Yokoyama, T., Kominami, R., Fujimoto, D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00882-5 · Cited by 52 · see citing works

Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets

Karagiannakos, A., Adamaki, M., Tsintarakis, A., Vojtěšek, B., Fåhræus, R., Zoumpourlis, V. C., & Karakostis, K. (2022) · Cancers · doi:10.3390/cancers14030664 · Cited by 55 · see citing works

Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment

Song, K. J., Choi, S., Kim, K., Hwang, H. S., Chang, E., Park, J. S., Shim, S. B., Choi, S., Heo, Y. J., Yang, D. Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54434-4 · Cited by 44 · see citing works

Why loss of Y? A pan-cancer genome analysis of tumors with loss of Y chromosome

Müller, P., Camacho, O. V., Yazbeck, A. M., Wölwer, C. B., Zhai, W., Schumacher, J., Heider, D., Buettner, R., Quaas, A., & Hillmer, A. M. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.02.024 · Cited by 43 · see citing works

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC

Zhang, F., Wang, J., Xu, Y., Cai, S., Li, T., Wang, G., Li, C., Zhao, L., & Hu, Y. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00243-7 · Cited by 41 · see citing works

Clonal driver neoantigen loss under EGFR TKI and immune selection pressures

Bakir, M. A., Reading, J. L., Gamble, S., Rosenthal, R., Uddin, I., Rowan, A., Przewrocka, J., Rogers, A., Wong, Y. N. S., Bentzen, A. K., et al. (2025) · Nature · doi:10.1038/s41586-025-08586-y · Cited by 40 · see citing works

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities

Chua, K. P., Teng, Y. H. F., Tan, A. C., Takano, A. M., Alvarez, J. J. S., Nahar, R. R., Rohatgi, N., Lai, G. G. Y., Aung, Z. W., Yeong, J. P.-S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4607 · Cited by 37 · see citing works

Mutation frequencies in endometrial cancer patients of different ethnicities and tumor grades: An analytical study

Althubiti, M. (2018) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_154_18 · Cited by 38 · see citing works

Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs

Vendrell, J. A., Mazières, J., Senal, R., Rouquette, I., Quantin, X., Pujol, J.-L., Roch, B., Bouidioua, A., Godreuil, S., Coyaud, É., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2683 · Cited by 38 · see citing works

Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer

Leong, T. L., Gayevskiy, V., Steinfort, D., de Massy, M. R., González-Rajal, Á., Marini, K. D., Stone, E. C. A., Chin, V. T., Havryk, A. P., Plit, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0536-1 · Cited by 37 · see citing works

The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations

Ma, F., Laster, K. V., & Dong, Z. (2022) · Nature Communications · doi:10.1038/s41467-022-33351-4 · Cited by 36 · see citing works

Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations

Passaro, A., Mok, T. S. K., Attili, I., Wu, Y.-L. L. C., Tsuboi, M., de Marinis, F., & Peters, S. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0459 · Cited by 36 · see citing works

The genomic landscape of young and old lung cancer patients highlights age‐dependent mutation frequencies and clinical actionability in young patients

Cai, L., Chen, Y., Tong, X., Wu, X., Bao, H., Shao, Y. W., Luo, Z., Wang, X., & Cao, Y. (2021) · International Journal of Cancer · doi:10.1002/ijc.33583 · Cited by 35 · see citing works

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer

Gini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38 · see citing works

Perioperative targeted therapy for oncogene-driven NSCLC

Liu, S. M., Zhang, J.-T., Zeng, K.-H., & Wu, Y.-L. L. C. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.007 · Cited by 34 · see citing works

Phasing analysis of lung cancer genomes using a long read sequencer

Sakamoto, Y., Miyake, S., Oka, M., Kanai, A., Kawai, Y., Nagasawa, S., Shiraishi, Y., Tokunaga, K., Kohno, T., Seki, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31133-6 · Cited by 31 · see citing works

Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic risk

Gorman, B. R., Ji, S., Francis, M., Sendamarai, A. K., Shi, Y., Devineni, P., Saxena, U., Partan, E. S., DeVito, A. K., Byun, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52129-4 · Cited by 35 · see citing works

Comprehensive molecular profiling of pulmonary pleomorphic carcinoma

Nagano, M., Kohsaka, S., Hayashi, T., Ueno, T., Kojima, S., Shinozaki‐Ushiku, A., Morita, S., Tsuda, M., Tanaka, S., Shinohara, T., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00201-3 · Cited by 32 · see citing works

Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?

Tamiya, M., Tamiya, A., Suzuki, H., Moriizumi, K., Nakahama, K., Taniguchi, Y., Kunimasa, K., Kimura, M., Inoue, T., Kuhara, H., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13544 · Cited by 31 · see citing works

Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors

Chang, S.-C., Lai, Y.-C., Chang, C.-Y., Huang, L.-K., Chen, S.-J., Tan, K. T., Yu, P., & Lai, J. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.07.008 · Cited by 31 · see citing works

New Frontiers for Molecular Pathology

Domagala-Kulawik, J. J. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00284 · Cited by 31 · see citing works

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib

Liu, Y., Ge, X., Pang, J., Zhang, Y., Zhang, H., Wu, H., Fan, F., & Liu, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671328 · Cited by 31 · see citing works

Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer

Kong, S. L., Liu, X., Tan, S. J., Tai, J. A., Phua, L. Y., Poh, H. M., Yeo, T., Chua, Y. W., Haw, Y. X., Ling, W. H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698551 · Cited by 31 · see citing works

Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement

Kim, M., Hwang, J., Kim, K., Hwang, S., Lee, H., Jung, J. Y., Lee, J. G., Cha, Y. J., & Shim, H. S. (2021) · Modern Pathology · doi:10.1038/s41379-021-00872-0 · Cited by 30 · see citing works

Racial and Ethnic Disparities in Survival Among People With Second Primary Cancer in the US

Sung, H., Nisotel, L. E., Sedeta, E. T., Islami, F., & Jemal, A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.27429 · Cited by 28 · see citing works

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

Iwama, E., Sakai, K., Hidaka, N., Inoue, K., Fujii, A., Nakagaki, N., Ota, K., Toyozawa, R., Azuma, K., Nakatomi, K., et al. (2019) · Cancer · doi:10.1002/cncr.32481 · Cited by 28 · see citing works

Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling

Testa, U., Pelosi, E., & Castelli, G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2017774 · Cited by 28 · see citing works

Structural Racism and Lung Cancer Risk

Bonner, S. N., Curley, R. J., Love, K., Akande, T., Akhtar, A., & Erhunmwunsee, L. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4897 · Cited by 26 · see citing works

Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges

Remón, J., Saw, S. P. L., Cortiula, F., Singh, P. K., Menis, J., Mountzios, G., & Hendriks, L. E. L. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1451 · Cited by 26 · see citing works

PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer

Saw, S. P. L., Ng, W. P., Zhou, S., Lai, G. G. Y., Tan, A. C., Ang, M., Lim, W., Kanesvaran, R., Ng, Q. S., Jain, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.012 · Cited by 25 · see citing works

A novel EZH2/NXPH4/CDKN2A axis is involved in regulating the proliferation and migration of non-small cell lung cancer cells

Yang, Z. Q., Wei, B., Anbang, Q., Yang, P., Chen, W., Zhen, D., & Qiu, X. (2021) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbab217 · Cited by 24 · see citing works

Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data

Xia, Z., Ou-yang, W., Hu, T., & Du, K. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.04.001 · Cited by 24 · see citing works

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients

Liang, H., Li, C., Zhao, Y., Zhao, S., Huang, J., Cai, X., Cheng, B., Xiong, S., Li, J., Wang, W., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s255967 · Cited by 23 · see citing works

The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations

Tan, J., Hu, C., Deng, P., Wan, R., Cao, L., Li, M., Yang, H., Gu, Q., An, J., & Jiang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646577 · Cited by 22 · see citing works

Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

Gristina, V., Mantia, M. L., Galvano, A., Cutaia, S., Barraco, N., Castiglia, M., Perez, A., Bono, M., Iacono, F., Greco, M., et al. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020016 · Cited by 23 · see citing works

Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung

Sivakumar, S., Lucas, F. A. S., Jakubek, Y. A., McDowell, T. L., Lang, W., Kallsen, N. A., Peyton, S., Davies, G. E., Fukuoka, J., Yatabe, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.020 · Cited by 21 · see citing works

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC

Kobayashi, K., & Tan, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044126 · Cited by 22 · see citing works

Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer

Li, C., Wang, Y., Su, K., Liu, Y., Wang, L., Zheng, B. J., Yan, N., Yuan, D., Zhang, Y., Xue, L., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1001 · Cited by 17 · see citing works

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project

Blons, H., Oudart, J.-B., Merlio, J., Debieuvre, D., de Fraipont, F., Audigier-Valette, C., Escande, F., Hominal, S., Bringuier, P., Fraboulet, S. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.008 · Cited by 19 · see citing works

CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

Hara, N., Ichihara, E., Kano, H., Ando, C., Morita, A., Nishi, T., Okawa, S., Nakasuka, T., Hirabae, A., Abe, M., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-99 · Cited by 20 · see citing works

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer

Nokin, M., Ambrogio, C., Nadal, E., & Santamarı́a, D. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.005 · Cited by 19 · see citing works

Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer

Keflee, R. D., Leong, K. H., Ogawa, S., Bignon, J. S., Chan, M. C., & Kong, K. W. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115262 · Cited by 17 · see citing works

Deep sequencing reveals the genomic characteristics of lung adenocarcinoma presenting as ground-glass nodules (GGNs)

Wu, N., Liu, S., Li, J., Hu, Z., Yan, S., Duan, H., Wu, D., Ma, Y., Li, S., Wang, X., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1086 · Cited by 16 · see citing works

Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer

Suda, K., Murakami, I., Obata, K., Sakai, K., Fujino, T., Koga, T., Ohara, S., Hamada, A., Soh, J., Nishio, K., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.010 · Cited by 15 · see citing works

Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma

Wu, X., Song, P., Guo, L., Ying, J., & Li, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888951 · Cited by 15 · see citing works

WMDS.net: a network control framework for identifying key players in transcriptome programs

Cheng, X., Amanullah, M., Liu, W., Liu, Y., Pan, X., Zhang, H., Xu, H., Liu, P., & Lü, Y. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad071 · Cited by 15 · see citing works

Application of large-scale targeted sequencing to distinguish multiple lung primary tumors from intrapulmonary metastases

Duan, J., Ge, M., Peng, J., Zhang, Y., Yang, L., Wang, T., Tian, Q., Rui, Y., Zhang, Y., & Cheng, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-75935-4 · Cited by 15 · see citing works

The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium

Chen, T. W., Pang, A. S. L., Puhaindran, M. E., Maw, M. M., Loong, H. H.-F., Sriuranpong, V., Chang, C., Mingmalairak, S., Hirose, T., Endo, M., et al. (2021) · Cancer Science · doi:10.1111/cas.14793 · Cited by 15 · see citing works

Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes

Kumar, S. U., Balasundaram, A., Hephzibah Cathryn, R., Varghese, R. P., Ramamoorthy, S., Ramanathan, G., Younes, S. N., Zayed, H., & Doss, C. G. P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105701 · Cited by 15 · see citing works

Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)

Tan, A. C., Teh, Y. L., Lai, G. G. Y., & Tan, D. S.-W. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1604228 · Cited by 15 · see citing works

Predicting EGFR gene mutation status in lung adenocarcinoma based on multifeature fusion

Jiang, Y., Ma, S., Xiao, W. L., Wang, J., Ding, Y., Zheng, Y., & Sui, X. (2023) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2023.104786 · Cited by 14 · see citing works

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer

Schatz, S., Falk, M., Jóri, B., Ramdani, H., Schmidt, S., Willing, E., Menon, R., Groen, H. J. M., Diehl, L., Kröger, M., et al. (2020) · Cancers · doi:10.3390/cancers12061685 · Cited by 14 · see citing works

Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma

Gu, W., Wang, N., Gu, W., Qiu, Y., Zhang, H., Liang, J., Zhou, T., Ma, L., Cai, W., Feng, W., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-457 · Cited by 13 · see citing works

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients

Karachaliou, N., Codony‐Servat, J., Bracht, J. W. P., Ito, M., Filipska, M., Pedraz‐Valdunciel, C., CHAIB-OUKADOUR, I., Bertrán-Alamillo, J., Cardona, A. F., Molina‐Vila, M. Á., et al. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656068 · Cited by 12 · see citing works

Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma

Hoppe, S., Jonas, C., Wenzel, M. C., Camacho, O. V., Arolt, C., Zhao, Y., Büttner, R., Quaas, A., Plum, P. S., & Hillmer, A. M. (2021) · Cancers · doi:10.3390/cancers13174300 · Cited by 15 · see citing works

Comprehensive genomic analysis of primary malignant melanoma of the esophagus reveals similar genetic patterns compared with epithelium-associated melanomas

Li, J., Liu, B., Ye, Q., Xiao, X., Yan, S., Guan, W., He, L., Wang, C., Yu, Z., Tai, Z., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01116-5 · Cited by 12 · see citing works

A phylogenetic approach to study the evolution of somatic mutational processes in cancer

Miura, S., Vu, T., Choi, J., Townsend, J. P., Karim, S., & Kumar, S. (2022) · Communications Biology · doi:10.1038/s42003-022-03560-0 · Cited by 12 · see citing works

The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment

Sueoka‐Aragane, N., Nakashima, C., Yoshida, H., Matsumoto, N., Iwanaga, K., Ebi, N., Nishiyama, A., Yatera, K., Kuyama, S., Fukuda, M., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3929 · Cited by 13 · see citing works

The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study

Chen, Y., Su, P., Huang, W., Chang, C., Yen, Y., Lin, C., & Tseng, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-22957-9 · Cited by 11 · see citing works

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma

Zhou, W., Liu, Z., Wang, Y., Zhang, Y., Qian, F., Lü, J., Wang, H., Gu, P., Hu, M., Chen, Y., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4543 · Cited by 11 · see citing works

Targeted Therapy in Early Stage Non-small Cell Lung Cancer

Liu, S., Liu, S. M., Zhong, W., & Wu, Y.-L. L. C. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00994-w · Cited by 12 · see citing works

High-throughput sequencing

Pradhan, D., Kumar, A., Singh, H., & Agrawal, U. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816548-5.00004-6 · Cited by 10 · see citing works

Comparing genomic landscape of early stage, treatment naïve and late stage, drug resistant EGFR-mutant lung adenocarcinomas

Nahar, R. R., Lee, Y. Y., Khng, A. J., Zhang, T., Takano, A. M., Liu, X., Alvarez, J. J. S., Zelichov, O., Ella, E., Barbash, Z. S., et al. (2017) · Canadian Journal of Biotechnology · doi:10.24870/cjb.2017-a231

Genomic landscape of lung adenocarcinoma in East Asians

Chen, J., Yang, H., Teo, A. S. M., Amer, L. B., Sherbaf, F. G., Tan, C. Q., Alvarez, J. J. S., Lu, B., Lim, J. Q., Takano, A. M., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0569-6 · Cited by 511 · see citing works

Abstract B2-54: Intratumor heterogeneity in never-smoker Asian EGFR mutant lung adenocarcinoma

Nahar, R. R., Zhai, W., Takano, A. M., Khng, A. J., Liu, X., Lim, C. H., Teo, A. S. M., Chan, C. X., Gogna, A., Lim, K., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.compsysbio-b2-54

Abstract A1-25: Intratumor heterogeneity in never-smoker Asian EGFR mutant lung adenocarcinoma

Nahar, R. R., Zhai, W., Takano, A. M., Khng, A. J., Liu, X., Lim, C. H., Teo, A. S. M., Chan, C. X., Gogna, A., Lim, K., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.transcagen-a1-25

Distinct Evolutionary Trajectories in Early Lung Adenocarcinoma: Age-Related Pathway with Epidermal Growth Factor Receptor–Associated Genome Doubling and Smoking-Driven PathwayPreprint

Goto, A., Nakaoka, H., Yoshida, M., Koyama, K., Miyabe, K., Zhou, J., Umakoshi, M., Takashima, S., Imai, K., Minamiya, Y., et al. (2026) · medRxiv · doi:10.64898/2026.07.21.26358543